A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma

Trial Profile

A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs GMI 1271 (Primary) ; Bortezomib
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 08 Feb 2017 Planned number of patients changed from 24 to 48.
    • 08 Feb 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.
    • 10 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top